# 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

> **NCT04150900** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Maryland, Baltimore** · enrollment: 7 (actual)

## Conditions studied

- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Bavituximab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04150900
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-13
- **Primary completion:** 2024-09-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04150900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04150900, "1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04150900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*